DexCom appoints Jacob Leach as CEO effective Jan 1, 2026; sets compensation terms

DEXCOM INC

Jacob S. Leach promoted to CEO from President/COO; effective Jan 1, 2026, succeeding Kevin Sayer on medical leave.
Annual base salary $1,150,000; target bonus 150% of base salary.
Granted RSUs valued at $7.5M vesting over 3 years; PSUs target $7.5M based on performance.
Sayer expected to return from medical leave ~March 2026; Foletta remains interim chairman.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.